C
C. Sanchez
Researcher at Hospital Universitario La Paz
Publications - 16
Citations - 730
C. Sanchez is an academic researcher from Hospital Universitario La Paz. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 9, co-authored 12 publications receiving 673 citations.
Papers
More filters
Journal ArticleDOI
Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients
Norella Kong Chiew Tong,Jiri Beran,Swee Ann Kee,Jose Luis Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,J R de Juanes,P. Arrazola,Francisco Calbo-Torrecillas,Eduardo López de Novales,Virginie Hamtiaux,Marc Lievens,Michel Stoffel +13 more
TL;DR: The improved immunogenicity profile and clinically acceptable reactogenicity of HB-AS04 vaccine are of key importance to provide a more rapid, enhanced, and longer seroprotection to these immunocompromised patients at risk for HB infection.
Journal ArticleDOI
Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters.
TL;DR: The data suggest that high TNF-alpha and low NPY serum levels are associated with anorexia and malnutrition among 55 clinically stable peritoneal dialysis patients and are also related to a poor nutritional status.
Journal ArticleDOI
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
Dorothee Kieninger,Eric Sheldon,Wen-Yuan Lin,Chong-Jen Yu,José M. Bayas,Julian J. Gabor,Meral Esen,Jose Luis Fernandez Roure,Silvia Narejos Perez,C. Sanchez,Yang Feng,Carine Claeys,Mathieu Peeters,Bruce L. Innis,Varsha K. Jain +14 more
TL;DR: QIV provided superior immunogenicity for the additional B strain compared with TIV, without interfering with antibody responses to the three shared antigens, suggesting that the candidate QIV is a viable alternative to TIV for use in adults, and could potentially improve protection against influenza B.
Journal ArticleDOI
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients
Norella C T Kong,Jiri Beran,S. A. Kee,J. L. Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,F. Calbo-Torrecillas,E. Lopez De Novales,Karthik Srinivasa,Michel Stoffel,Bernard Hoet +11 more
TL;DR: In this paper, the authors evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in prehemodialysis and hemodialysis patients.
Journal Article
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Commentary
J. K. Unger,H. Peters,Norella C T Kong,Jiri Beran,S. A. Kee,J. L. Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,F. Calbo-Torrecillas,E. Lopez De Novales,Karthik Srinivasa,Michel Stoffel,Bernard Hoet +13 more
TL;DR: In this population of prehemodialysis and hemodialysis patients, the HBV-AS04 was immunogenic, safe, and well-tolerated both as a booster dose after HBV -AS04 or standard hepatitis B vaccine priming.